Data For Two HER2-Positive Breast Cancer Drugs Impress, Including On Overall Survival

AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.

Two new breast cancer drugs hit their target in pivotal trials • Source: Shutterstock

Metastatic HER2-positive breast cancer patients who have run out of treatment options soon could have two new therapies that have shown progression-free survival (PFS) and overall survival (OS) benefits in clinical trials. However, it's still unclear how the launch of two new drugs for the challenging patient population might play out in the commercial market and how the two drugs could be sequenced.

Partners AstraZeneca PLC and Daiichi Sankyo Co. Ltd. presented data on the antibody-drug conjugate (ADC) trastuzumab deruxtecan (DS-8201)...

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

04 Jul 2025

• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

04 Jul 2025

• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.